DNA-topoisomerase II: Cellular targets of antineoplastic agents
Le Guern, M.
Pathologie-Biologie 35(4): 343-345
1987
ISSN/ISBN: 0369-8114 PMID: 3035465 Document Number: 299672
Document emailed within 1 workday
Related Documents
Szmigiero, L. 1988: Topoisomerase Ii as a cellular receptor of various antineoplastic drugs Postepy Biochemii 34(3): 147-152Tokutome, A.; Taniguchi, R.; Maeda, K.; Saito, Y.; Ishii, T.; Minami, S.; Wano, Y.; Ota, T.; Saitoh, H.; Takeda, K. 2018: The Usefulness of a Pamphlet for Preventing Exposure to Antineoplastic Agents at Cancer Patients' Homes and an Awareness Survey for Pharmacists about Providing Information to Cancer Patients about Exposure to Antineoplastic Agents Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(5): 833-839
Pollack, S.B.; Nelson, K.; Grausz, J.D. 1976: Separation of effector cells mediating antibody-dependent cellular cytotoxicity (ADC) to erythrocyte targets from those mediating ADC to tumor targets Journal of Immunology 116(4): 944-946
Tanabe, K.; Ikegami, Y.; Ishida, R.; Andoh, T. 1991: Inhibition of topoisomerase Ii by antitumor agents bis(2,6-dioxopiperazine) derivatives Cancer Research 51(18): 4903-4908
Morjani, H.; Riou, J.F.; Nabiev, I.; Lavelle, F.; Manfait, M. 1993: Molecular and cellular interactions between intoplicine, DNA, and topoisomerase II studied by surface-enhanced Raman scattering spectroscopy Cancer Research 53(20): 4784-4790
De Isabella, P.; Capranico, G.; Palumbo, M.; Sissi, C.; Krapcho, A.P.; Zunino, F. 1993: Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects Molecular Pharmacology 43(5): 715-721
Wang, L.G.; Liu, X.M.; Ji, X.J. 1991: Determination of DNA topoisomerase Ii activity from L1210 cells--a target for screening antitumor agents Zhongguo Yao Li Xue Bao 12(2): 108-114
1971: Chemistry of antineoplastic agents Minerva Medica 62(28): 1492
Mitolo-chieppa, D.; Ceci, A. 1974: Neurotoxicity of some antineoplastic agents Bollettino della Societa Italiana di Biologia Sperimentale 50(17): 1333-1359
Aiello, E.; Dattolo, G.; Cirrincione, G.; Almerico, A.M.; Diana, P.; Grimaudo, S.; Mingoia, F.; Barraja, P. 1995: Azolophenanthridines as antineoplastic agents Farmaco 50(6): 365-368
Shigeoka, Y.; Shimizu, E. 2007: Myelosuppression due to antineoplastic agents Nihon Rinsho. Japanese Journal of Clinical Medicine 65(Suppl 8): 287-293
Wada, T.; Matsui, H. 2013: Research development of novel antineoplastic agents Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 142(4): 149
Berti, T. 1970: Specific histotropism of antineoplastic agents La Clinica Terapeutica 55(4): 293-303
Pettit, G.R.; Srirangam, J.K.; Barkoczy, J.; Williams, M.D.; Boyd, M.R.; Hamel, E.; Pettit, R.K.; Hogan, F.; Bai, R.; Chapuis, J.C.; McAllister, S.C.; Schmidt, J.M. 1998: Antineoplastic agents 365. Dolastatin 10 SAR probes Anti-Cancer Drug Design 13(4): 243-277
Lown, J.W. 1988: Lexitropsins: rational design of DNA sequence reading agents as novel anti-cancer agents and potential cellular probes Anti-Cancer Drug Design 3(1): 25-40
Schmoll, H.J.; Hiddemann, W.; Rustum, Y.; Köhne-Wömpner, C.H. 1992: The emerging role for biomodulation of antineoplastic agents Seminars in Oncology 19(2 Suppl 3: 1-3
Kato, T.; Nemoto, R. 1982: Clinical application of microencapsulated antineoplastic agents Nihon Rinsho. Japanese Journal of Clinical Medicine 40(2): 478-488
Orfi, L.; Wáczek, F.; Szabó, M.; Kövesdi, I.; Mészáros, G.; Idei, M.; Horváth, A.; Hollósy, F.; Mák, M.; Szegedi, Z.; Szende, B.; Kéri, G.; Noszál, B. 1999: Preparation and characterization of potential antineoplastic agents Acta Pharmaceutica Hungarica 69(3): 115-122
Sakurai, Y. 1975: Deveolpment of new antineoplastic agents and their clinical characteristics Nihon Rinsho. Japanese Journal of Clinical Medicine 33(5): 1892-1896
Babaian, I.S.; Khudaverdian, N.V.; Karapetian, L.G.; Kazarian, R.S.; Sogomonian, L.R. 1997: Comparative study of three antineoplastic alkylating agents on DNA Biofizika 42(2): 542-543